ArticleCancer reports (Hoboken, N.J.)2025
Delayed Abscopal Response 3 Years After Robotic Stereotactic Body Radiation Therapy for Renal Cell Carcinoma: A Case Report.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) is the most common malignant tumor of the kidney in adults, with poor prognosis in advanced or metastatic stages. Although traditionally considered radioresistant, RCC has shown a promising response to stereotactic body radiation therapy (SBRT), which not only offers local tumor control but may also induce an abscopal effect, resulting in regression of distant metastases. CASE: A 54-year-old male with a history of right RCC underwent radical nephrectomy in 2000, followed by partial nephrectomy for a left kidney recurrence in 2005. In 2011, imaging revealed a second recurrence in the left kidney. In 2013, after declining further surgery, he was treated with SBRT for the recurrent left renal lesion. Follow-up imaging revealed a stable renal mass and a solid right lung nodule. Retrospective analysis of prior imaging suggested the presence of pulmonary metastases concurrent with the renal recurrence. The pulmonary nodule progressively enlarged until November 2016 but then spontaneously regressed by November 2017 without any additional systemic or local interventions, and remained stably reduced in size thereafter. Serial imaging from 2018 showed no evidence of new metastatic disease, and the left renal lesion exhibited partial regression. The pulmonary metastasis remained stable, consistent with the occurrence of an abscopal effect that persisted for 3 years. The patient ultimately passed away in 2024 from unrelated causes.
conclusionThis case demonstrates the potential of SBRT to induce a systemic abscopal response in metastatic RCC, with sustained control of pulmonary metastasis over 3 years. The findings suggest that SBRT may play a critical role in managing metastatic RCC, warranting further research into its synergy with immunotherapy for long-term therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.